Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telo Genomics Corp ( (TSE:TELO) ) has shared an update.
Telo Genomics Corp. has launched a non-brokered private placement of secured convertible debentures to raise up to $1.2 million, offering 15% annual interest with a nine-month term and a conversion price of $0.05 per share, along with detachable warrants exercisable at $0.08 per share. The capital is earmarked for lab trials and general working capital, and the financing structure, which includes a four-month hold period and is contingent on TSX Venture Exchange approval, underscores the company’s need to fund ongoing clinical and product development efforts as it advances its telomere-based diagnostics platform toward broader commercialization.
The most recent analyst rating on (TSE:TELO) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on Telo Genomics Corp stock, see the TSE:TELO Stock Forecast page.
Spark’s Take on TSE:TELO Stock
According to Spark, TipRanks’ AI Analyst, TSE:TELO is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, persistent losses, and cash burn with negative equity), with technicals also indicating a broader downtrend. Corporate events provide some positive clinical/validation progress, but valuation remains constrained by ongoing losses and no dividend support.
To see Spark’s full report on TSE:TELO stock, click here.
More about Telo Genomics Corp
Telo Genomics Corp. is a Toronto-based biotechnology company specializing in a proprietary telomere analysis platform used to develop liquid biopsy and related diagnostic technologies for oncology and neurological diseases. By combining 3D telomere quantitative analysis with molecular biology and artificial intelligence, the company aims to deliver simple, accurate prognostic and diagnostic tools that support pathologists, clinicians, researchers and drug developers, with a lead application, Telo-MM, focused on improving treatment decision-making in multiple myeloma.
Average Trading Volume: 166,825
Technical Sentiment Signal: Sell
Current Market Cap: C$5.02M
Find detailed analytics on TELO stock on TipRanks’ Stock Analysis page.